Stereotaxis

STXS

Medical - Equipment & Services · Healthcare

Price

$1.55

-0.10 (-6.06%)

Market Cap

$151.5M

Exchange

New York Stock Exchange Arca

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+20.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 75.6M (2021) → 91.0M (2025)

Stereotaxis makes robotic systems used by doctors to perform heart procedures. Its main product, the Genesis robotic magnetic navigation system, uses magnets to guide thin wires through a patient's heart to treat abnormal heart rhythms, a condition called arrhythmia. The company sells its equipment to hospitals and cardiac catheterization labs, primarily in the United States and Europe.

Stereotaxis earns money by selling its robotic systems to hospitals and then charging ongoing fees for disposable supplies, service contracts, and software used during each procedure. The company is small, with a market cap around $200 million, and its technology is specialized enough that few direct competitors offer the same magnetic navigation approach. However, Stereotaxis is currently losing significant money, with deep operating losses, so its main challenge is expanding the number of hospitals using its systems and growing recurring revenue fast enough to reach profitability before it needs additional funding.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-15.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+10.7% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$9M/ year

→ Flat (-4% vs prior year)

29.0% of revenue

1.6x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

29.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~12 months

$15M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Stereotaxis's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

60.3%

Premium pricing power — 60.3% gross margin

Operating Margin

-82.4%

Losing money on operations — -82.4%

ROCE

-26.4%

Weak — -26.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+13.4%

Fast-growing sales (13.4% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-49.8%

Burning cash (-49.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial